TTAA Specific DNA Transposon Platform for Non-Viral CAR Integration

Online Inquiry

Background Service Technical Specifications Workflow Highlights FAQs Contact

Current non-viral CAR engineering faces major bottlenecks, low transgene integration efficiency, random genomic insertion risks, and silencing of therapeutic cassettes, which collectively hinder durable and safe CAR expression in primary T cells. To address these limitations, we have established the TTAA-specific DNA Transposon Platform for Non-Viral CAR Integration, which directs CAR transgenes to TTAA chromosomal sites with high enzymatic activity. Our service offers custom vector design, optimized transposase formulations, and streamlined electroporation protocols tailored for both research and preclinical scales. Our platform ensures robust, long‑term CAR expression with minimal off‑target effects, significantly reducing clonal variability and genotoxicity risks, thereby providing you with a reliable and cost‑effective solution for next‑generation cell therapy development.

Introduction

Transposon systems are versatile, non-viral genetic tools that enable stable chromosomal integration of therapeutic transgenes through a precise "cut-and-paste" mechanism, offering a safe and efficient alternative to viral vectors for immune cell engineering. The TTAA-specific transposon system, derived from insect cells, features a large cargo capacity and seamless excision capability, allowing for high-efficiency integration at TTAA target sites with minimal genomic footprint.

Fig.1 The TTAA-specific DNA transposon system facilitates the integration of target genes into the host chromosome. ¹

Our Service

Our TTAA-specific DNA transposon platform represents a next-generation non-viral system for efficient CAR gene delivery and stable genomic integration into primary T cells. By leveraging a highly active transposase, this technology enables rapid, cost-effective, and safe manufacturing of CAR-T products with durable transgene expression. We provide partners with a fully scalable solution, from construct design to clinical-grade production, accelerating your path from research to transformative cell therapies.

Technical Specifications

This non-viral, TTAA-specific DNA transposon platform delivers robust, high-efficiency genomic integration across diverse taxa.

Featured services of TTAA-specific DNA transposon platform for non-viral CAR integration at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Peripheral blood mononuclear cells (PBMCs) or T cells.
TTAA-specific DNA transposon.

Key Steps:

Workflow of TTAA-specific DNA transposon platform for non-viral CAR integration at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Cryopreserved or fresh non-viral transposon CAR-cell formulations.
Assessment of transduction efficiency.

Key Advantages

Superior Safety Profile: Our platform originates from non-pathogenic sources, fundamentally eliminating the immunogenicity and insertional mutagenesis risks associated with viral vectors.
Enhanced Cargo Capacity: The transposon system exhibits a relatively high payload tolerance, offering superior flexibility for the construction of complex or multi-genetic CAR constructs.
Stable and Sustained Transgene Expression: Through the specific activity of the transposase, the CAR gene is stably integrated into the genomic TTAA sites, ensuring durable and long-term expression of the therapeutic transgene.

FAQ

Q1: Does the random integration of the transposon pose a risk of insertional mutagenesis?

A1: The platform exhibits a close-to-random integration profile with no preference for transcription start sites or coding sequences, significantly mitigating the risk of genotoxic events and secondary malignancies, a key advantage over viral vectors and some other transposon systems.

Q2: How long do the CAR-T cells persist in the body after infusion?

A2: CAR-T cells engineered with this platform can expand rapidly after infusion and remain detectable for over 2 years, demonstrating the stable and sustained expression of the therapeutic transgene.

Why Choose Us?

Our TTAA-specific transposon platform offers a uniquely balanced solution, uncompromised safety, dramatically reduced manufacturing timelines and costs, and stable CAR expression through targeted genomic integration. Backed by robust clinical data and a streamlined workflow, we empower partners to accelerate next-generation cell therapies from discovery to patients efficiently and reliably.

Customer Reviews

"Developing next-generation dual-targeted CAR-T therapies for solid malignancies presented a critical bottleneck due to the strict cargo limitations of conventional lentiviral vectors. Shifting to this TTAA-specific DNA transposon service seamlessly accommodated our large genetic circuits, while demonstrating exceptional transcriptional stability and robust, prolonged anti-tumor efficacy within murine models." Dr. Elena Rostova.

"Mitigating insertional mutagenesis remains a paramount regulatory hurdle in CAR-T CMC development. This service's TTAA-specific platform provides footprint-free excision and high-fidelity integration; comprehensive whole-genome sequencing confirmed zero unintended genomic disruption. Additionally, the harvested CAR-T cells retained superb expansion capabilities alongside a highly potent stem cell memory phenotype." Dr. Hai Lin.

How to contact us?

Interested in advancing your CAR-T programs with a non-viral integration system that combines speed, affordability, and an enhanced safety profile? Our specialist team is ready to engage on tailored development strategies, joint research ventures, and flexible licensing arrangements. Connect with us to evaluate how our TTAA-targeting transposon technology may streamline your translational path and support scalable, next-generation cell therapy manufacturing. We are eager to collaborate on bringing innovative treatments to patients.

Reference

Sato, Masahiro et al. "piggyBac-Based Non-Viral In vivo Gene Delivery Useful for Production of Genetically Modified Animals and Organs." Pharmaceutics vol. 12,3 277. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/pharmaceutics12030277.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.